Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.

[1]  J. Seidman,et al.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.

[2]  Rosie Qin,et al.  Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab. , 2016, International journal of radiation oncology, biology, physics.

[3]  J. Crawford,et al.  Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. , 2016, Lung cancer.

[4]  R. Jagsi,et al.  The Promise of the Abscopal Effect and the Future of Trials Combining Immunotherapy and Radiation Therapy. , 2016, International journal of radiation oncology, biology, physics.

[5]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[6]  G. Gibney,et al.  Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  S. Swetter,et al.  A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. , 2015, International journal of radiation oncology, biology, physics.

[8]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[9]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Wolchok,et al.  Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[12]  Y. Yamada,et al.  Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. , 2015, International journal of radiation oncology, biology, physics.

[13]  A. Ng,et al.  A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab , 2015, Oncoimmunology.

[14]  J. Machiels,et al.  KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer. , 2015 .

[15]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[16]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[17]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[18]  F. Cappuzzo,et al.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[19]  V. Sridharan,et al.  Immune effects of targeted radiation therapy for cancer. , 2015, Discovery medicine.

[20]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[21]  P. Ott,et al.  PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma , 2015, Oncotarget.

[22]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[23]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[24]  M. Suarez‐Almazor,et al.  Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience , 2014, Oncogene.

[25]  Antoni Ribas,et al.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.

[26]  M. Milano,et al.  Radical irradiation of extracranial oligometastases. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Joshua Jones,et al.  Role of radiation therapy in palliative care of the patient with cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Ascierto,et al.  Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy , 2014, Oncoimmunology.

[29]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Brady T. West,et al.  Ipilimumab and radiation therapy for melanoma brain metastases , 2013, Cancer medicine.

[31]  Y. Yamada,et al.  Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma , 2013, Cancer Immunology Research.

[32]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[33]  J. Golfinos,et al.  Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery , 2013, Melanoma research.

[34]  Sacha Gnjatic,et al.  The abscopal effect associated with a systemic anti-melanoma immune response. , 2013, International journal of radiation oncology, biology, physics.

[35]  J. Knisely,et al.  Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. , 2012, Journal of neurosurgery.

[36]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[37]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[38]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[39]  N. Kawashima,et al.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.